Docetaxel-Cisplatin-Fluorouracil Induction Chemotherapy for Larynx Preservation in Patients with Locally Advanced Hypopharyngeal Cancer: Predictive Factors of Oncologic and Functional Outcomes.

dysphagia hypopharyngeal cancer induction chemotherapy larynx preservation predictive factors survival

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
01 Feb 2023
Historique:
received: 27 12 2022
revised: 20 01 2023
accepted: 30 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

The aims of this study were to evaluate the clinical outcomes and their predictive factors in locally advanced hypopharyngeal cancer (HC) patients included in a docetaxel-cisplatin-fluorouracil induction chemotherapy (ICT)-based larynx preservation (LP) program. Between 2005 and 2021, 82 patients with a locally advanced resectable HC who received ICT in an LP program were included in this retrospective study. The predictors of oncologic and swallowing outcomes were determined in univariate and multivariate analyses. The three- and five-year overall survival (OS) rates were 67 and 54%, respectively. The T4 tumor stage was the only predictive factor of poor response to ICT ( The T stage, number of ICT cycles performed and response to ICT are the main predictors of oncologic outcomes. Patients with T4 HC are poor candidates for LP and should be referred to immediate radical surgery.

Sections du résumé

BACKGROUND BACKGROUND
The aims of this study were to evaluate the clinical outcomes and their predictive factors in locally advanced hypopharyngeal cancer (HC) patients included in a docetaxel-cisplatin-fluorouracil induction chemotherapy (ICT)-based larynx preservation (LP) program.
METHODS METHODS
Between 2005 and 2021, 82 patients with a locally advanced resectable HC who received ICT in an LP program were included in this retrospective study. The predictors of oncologic and swallowing outcomes were determined in univariate and multivariate analyses.
RESULTS RESULTS
The three- and five-year overall survival (OS) rates were 67 and 54%, respectively. The T4 tumor stage was the only predictive factor of poor response to ICT (
CONCLUSIONS CONCLUSIONS
The T stage, number of ICT cycles performed and response to ICT are the main predictors of oncologic outcomes. Patients with T4 HC are poor candidates for LP and should be referred to immediate radical surgery.

Identifiants

pubmed: 36769779
pii: jcm12031131
doi: 10.3390/jcm12031131
pmc: PMC9918009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancers (Basel). 2020 Mar 03;12(3):
pubmed: 32138168
J Natl Cancer Inst. 2009 Apr 1;101(7):498-506
pubmed: 19318632
Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Jun;136(3S):S27-S33
pubmed: 30846293
Radiat Oncol. 2020 Dec 14;15(1):281
pubmed: 33317602
Head Neck. 2022 Sep;44(9):2018-2029
pubmed: 35915867
Head Neck. 2012 Feb;34(2):270-81
pubmed: 22228621
J Clin Oncol. 2013 Mar 1;31(7):853-9
pubmed: 23341517
Head Neck. 2019 Mar;41(3):569-576
pubmed: 30570183
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2681-7
pubmed: 26395117
J Laryngol Otol. 2018 May;132(5):385-400
pubmed: 29891019
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594-601
pubmed: 26068492
Dysphagia. 1999 Summer;14(3):139-45
pubmed: 10341109
Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13
pubmed: 16946667
Front Oncol. 2019 May 31;9:419
pubmed: 31214491
J Natl Cancer Inst. 2015 Dec 16;108(4):
pubmed: 26681800
Head Neck. 2013 Nov;35(11):1641-6
pubmed: 23322545

Auteurs

Pierre Mattei (P)

Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Jocelyn Gal (J)

Department of Statistics, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Emmanuel Chamorey (E)

Department of Statistics, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Olivier Dassonville (O)

Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Gilles Poissonnet (G)

Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Déborah Aloi (D)

Department of Radiation Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Médéric Barret (M)

Department of Radiation Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Inga Safta (I)

Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Esma Saada (E)

Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Anne Sudaka (A)

Department of Pathology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Dorian Culié (D)

Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.

Alexandre Bozec (A)

Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France.
Faculty of Medecine, Côte d'Azur University, 06107 Nice, France.

Classifications MeSH